IGV-001 extended median overall survival to 20.3 months, 6.3 months longer than placebo, in newly diagnosed glioblastoma patients. The phase 2b trial showed a favorable safety profile, consistent with ...
IGV has outperformed the S&P 500 by over 15 percentage points since my bullish call, driven by strong momentum and a solid technical setup. The ETF offers exposure to high-growth US large-cap software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results